{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T16:31:47Z","timestamp":1783096307284,"version":"3.54.6"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Guangzhou Municipal Science and Technology Program","award":["2023A04J2218"],"award-info":[{"award-number":["2023A04J2218"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Abdom Radiol"],"DOI":"10.1007\/s00261-024-04767-x","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T10:31:16Z","timestamp":1736418676000},"page":"3126-3136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Noninvasive identification of HER2 status by integrating multiparametric MRI-based radiomics model with the vesical imaging-reporting and data system (VI-RADS) score in bladder urothelial carcinoma"],"prefix":"10.1007","volume":"50","author":[{"given":"Cheng","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shurong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingwu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daohu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"4767_CR1","doi-asserted-by":"crossref","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun;74(3):229\u2013263.","DOI":"10.3322\/caac.21834"},{"issue":"1","key":"4767_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"J Alfred Witjes","year":"2024","unstructured":"Alfred Witjes J, Max Bruins H, Carri\u00f3n A, Cathomas R, Comp\u00e9rat E, Efstathiou JA, Fietkau R, Gakis G, Lorch A, Martini A, Mertens LS, Meijer RP, Milowsky MI, Neuzillet Y, Panebianco V, Redlef J, Rink M, Rouanne M, Thalmann GN, S\u00e6bj\u00f8rnsen S, Veskim\u00e4e E, van der Heijden AG. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines. Eur Urol. 2024 Jan;85(1):17-31.","journal-title":"Eur Urol."},{"key":"4767_CR3","doi-asserted-by":"crossref","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, G\u00fcm\u00fc\u015f M, Mar N, Loriot Y, Fl\u00e9chon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, van der Heijden MS; EV-302 Trial Investigators. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med. 2024 Mar 7;390(10):875\u2013888.","DOI":"10.1056\/NEJMoa2312117"},{"issue":"13","key":"4767_CR4","doi-asserted-by":"publisher","first-page":"1233196","DOI":"10.3389\/fonc.2023.1233196","volume":"10","author":"F Wen","year":"2024","unstructured":"Wen F, Lin T, Zhang P, Shen Y. RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib\/II study (HOPE-03). Front Oncol. 2024 Jan 10;13:1233196.","journal-title":"Front Oncol."},{"issue":"8","key":"4767_CR5","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.ccell.2021.06.001","volume":"39","author":"AB Hanker","year":"2021","unstructured":"Hanker AB, Brown BP, Meiler J, Mar\u00edn A, Jayanthan HS, Ye D, Lin CC, Akamatsu H, Lee KM, Chatterjee S, Sudhan DR, Servetto A, Brewer MR, Koch JP, Sheehan JH, He J, Lalani AS, Arteaga CL. Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2\/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity. Cancer Cell. 2021 Aug 9;39(8):1099-1114.","journal-title":"Cancer Cell."},{"issue":"16","key":"4767_CR6","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1111\/jcmm.17828","volume":"27","author":"D Wang","year":"2023","unstructured":"Wang D, Hao S, He H, Zhang J, You G, Wu X, Zhang R, Meng X, Cui X, Bai J, Fu S, Yu J. Contribution of PGAP3 co-amplified and co-overexpressed with ERBB2 at 17q12 involved poor prognosis in gastric cancer. J Cell Mol Med. 2023 Aug;27(16):2424-2436.","journal-title":"J Cell Mol Med."},{"issue":"5","key":"4767_CR7","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/tox.23076","volume":"36","author":"TC Chuang","year":"2021","unstructured":"Chuang TC, Wu K, Lin YY, Kuo HP, Kao MC, Wang V, Hsu SC, Lee SL. Dual down-regulation of EGFR and ErbB2 by berberine contributes to suppression of migration and invasion of human ovarian cancer cells. Environ Toxicol. 2021 May;36(5):737-747.","journal-title":"Environ Toxicol."},{"issue":"8","key":"4767_CR8","doi-asserted-by":"publisher","first-page":"e617","DOI":"10.1093\/oncolo\/oyad070","volume":"28","author":"L Zhou","year":"2023","unstructured":"Zhou L, Shao Z, Liu Y, Yan X, Li J, Wu X, Tang B, Li S, Cui C, Chi Z, Si L, Kong Y, Mao L, Lian B, Wang X, Bai X, Dai J, Guo J, Sheng X. HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population. Oncologist. 2023 Aug 3;28(8):e617-e624.","journal-title":"Oncologist."},{"issue":"2","key":"4767_CR9","doi-asserted-by":"publisher","first-page":"63.e9","DOI":"10.1016\/j.urolonc.2021.06.021","volume":"40","author":"D Sikic","year":"2022","unstructured":"Sikic D, Eckstein M, Weyerer V, Kubon J, Breyer J, Roghmann F, Kunath F, Keck B, Erben P, Hartmann A, Wirtz RM, Wullich B, Taubert H, Wach S. High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer. Urol Oncol. 2022 Feb;40(2):63.e9-63.e18.","journal-title":"Urol Oncol."},{"issue":"14","key":"4767_CR10","doi-asserted-by":"publisher","first-page":"1301510","DOI":"10.3389\/fimmu.2023.1301510","volume":"8","author":"W Nam","year":"2023","unstructured":"Nam W, Chae HK, Jung Y, Kang H, Park M, Choi A, Park JY, Eom DW, Kim SJ. HER2 positivity predicts BCG unresponsiveness and adaptive immune cell exhaustion in EORTC risk-stratified cohort of bladder cancer. Front Immunol. 2023 Dec 8;14:1301510.","journal-title":"Front Immunol."},{"issue":"4","key":"4767_CR11","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.euo.2023.10.003","volume":"7","author":"X Tan","year":"2024","unstructured":"Tan X, Liu Z, Cai T, Wang Y, Wu Z, Qin Z, Li Z, Liu Z, Yuan G, Zhou Q, Yao K. Prognostic Significance of HER2 Expression in Patients with Bacillus Calmette-Gu\u00e9rin-exposed Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2024 Aug;7(4):760-769.","journal-title":"Eur Urol Oncol."},{"key":"4767_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103042","volume":"61","author":"AGV Bitencourt","year":"2020","unstructured":"Bitencourt AGV, Gibbs P, Rossi Saccarelli C, Daimiel I, Lo Gullo R, Fox MJ, Thakur S, Pinker K, Morris EA, Morrow M, Jochelson MS. MRI-based machine learning radiomics can predict HER2 expression level and pathologic response after neoadjuvant therapy in HER2 overexpressing breast cancer. EBioMedicine. 2020 Nov;61:103042.","journal-title":"EBioMedicine."},{"key":"4767_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2024.111573","volume":"177","author":"T Zhan","year":"2024","unstructured":"Zhan T, Dai J, Li Y. Noninvasive identification of HER2-zero, -low, or -overexpressing breast cancers: Multiparametric MRI-based quantitative characterization in predicting HER2-low status of breast cancer. Eur J Radiol. 2024 Aug;177:111573.","journal-title":"Eur J Radiol."},{"issue":"1","key":"4767_CR14","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s13244-024-01840-3","volume":"15","author":"Z Wei","year":"2024","unstructured":"Wei Z, Bai X, Xv Y, Chen SH, Yin S, Li Y, Lv F, Xiao M, Xie Y. A radiomics-based interpretable machine learning model to predict the HER2 status in bladder cancer: a multicenter study. Insights Imaging. 2024 Oct 28;15(1):262.","journal-title":"Insights Imaging."},{"issue":"3","key":"4767_CR15","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.eururo.2018.04.029","volume":"74","author":"V Panebianco","year":"2018","unstructured":"Panebianco V, Narumi Y, Altun E, Bochner BH, Efstathiou JA, Hafeez S, Huddart R, Kennish S, Lerner S, Montironi R, Muglia VF, Salomon G, Thomas S, Vargas HA, Witjes JA, Takeuchi M, Barentsz J, Catto JWF. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol. 2018 Sep;74(3):294-306.","journal-title":"Eur Urol."},{"issue":"13","key":"4767_CR16","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.3390\/diagnostics13132300","volume":"13","author":"B Boca","year":"2023","unstructured":"Boca B, Caraiani C, Telecan T, Pintican R, Lebovici A, Andras I, Crisan N, Pavel A, Diosan L, Balint Z, Lupsor-Platon M, Buruian MM. MRI-Based Radiomics in Bladder Cancer: A Systematic Review and Radiomics Quality Score Assessment. Diagnostics (Basel). 2023 Jul 6;13(13):2300.","journal-title":"Diagnostics (Basel)."},{"issue":"12","key":"4767_CR17","doi-asserted-by":"publisher","first-page":"8821","DOI":"10.1007\/s00330-023-09960-y","volume":"33","author":"G Chen","year":"2023","unstructured":"Chen G, Fan X, Wang T, Zhang E, Shao J, Chen S, Zhang D, Zhang J, Guo T, Yuan Z, Tang H, Yu Y, Chen J, Wang X. A machine learning model based on MRI for the preoperative prediction of bladder cancer invasion depth. Eur Radiol. 2023 Dec;33(12):8821-8832.","journal-title":"Eur Radiol."},{"issue":"5","key":"4767_CR18","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1002\/jmri.26327","volume":"49","author":"X Xu","year":"2019","unstructured":"Xu X, Zhang X, Tian Q, Wang H, Cui LB, Li S, Tang X, Li B, Dolz J, Ayed IB, Liang Z, Yuan J, Du P, Lu H, Liu Y. Quantitative Identification of Nonmuscle-Invasive and Muscle-Invasive Bladder Carcinomas: A Multiparametric MRI Radiomics Analysis. J Magn Reson Imaging. 2019 May;49(5):1489-1498.","journal-title":"J Magn Reson Imaging."},{"issue":"11","key":"4767_CR19","doi-asserted-by":"publisher","first-page":"e889","DOI":"10.1016\/j.crad.2023.07.020","volume":"78","author":"W Wang","year":"2023","unstructured":"Wang W, Wang K, Qiu J, Li W, Wang X, Zhang Y, Wang X, Wu J. MRI-based radiomics analysis of bladder cancer: prediction of pathological grade and histological variant. Clin Radiol. 2023 Nov;78(11):e889-e897.","journal-title":"Clin Radiol."},{"issue":"20","key":"4767_CR20","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018 Jul;36(20):2105-2122.","journal-title":"J Clin Oncol."},{"key":"4767_CR21","doi-asserted-by":"publisher","first-page":"1230395","DOI":"10.3389\/fphar.2023.1230395","volume":"14","author":"Y Wei","year":"2023","unstructured":"Wei Y, Zhang R, Yu C, Hong Z, Lin L, Li T, Chen J. Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center's real-world study. Front Pharmacol. 2023 Aug;14:1230395.","journal-title":"Front Pharmacol."},{"issue":"3","key":"4767_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102085","volume":"22","author":"A Wang","year":"2024","unstructured":"Wang A, Chen M, Li D, Shi J, Tang W, Zhang Z, Ren S. Disitamab Vedotin Alone or in Combination With Immune Checkpoint Inhibitors in Bladder-Sparing Treatment of Muscle-Invasive Bladder Cancer: A Real-World Study. Clin Genitourin Cancer. 2024 Jun;22(3):102085.","journal-title":"Clin Genitourin Cancer."},{"key":"4767_CR23","doi-asserted-by":"publisher","first-page":"1233196","DOI":"10.3389\/fonc.2023.1233196","volume":"13","author":"F Wen","year":"2024","unstructured":"Wen F, Lin T, Zhang P, Shen Y. RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib\/II study (HOPE-03). Front Oncol. 2024 Jan;13:1233196.","journal-title":"Front Oncol."},{"issue":"2","key":"4767_CR24","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1097\/JS9.0000000000000859","volume":"110","author":"SW Kim","year":"2024","unstructured":"Kim SW, Yu H, Kim Y, Nam KH, Chae HK, Nam W, Eom DW, Park JY, Kim SJ. HER2 overexpression predicts pathological T2 stage and improved survival in de novo muscle-invasive bladder cancer after immediate radical cystectomy: a retrospective cohort study. Int J Surg. 2024 Feb;110(2):847-858.","journal-title":"Int J Surg."},{"issue":"2","key":"4767_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.urolonc.2021.11.008","volume":"40","author":"SB Jazayeri","year":"2022","unstructured":"Jazayeri SB, Dehghanbanadaki H, Hosseini M, Taghipour P, Alam MU, Balaji KC, Bandyk M. Diagnostic accuracy of vesical imaging-reporting and data system (VI-RADS) in suspected muscle invasive bladder cancer: A systematic review and diagnostic meta-analysis. Urol Oncol. 2022 Feb;40(2):45-55.","journal-title":"Urol Oncol."},{"issue":"4","key":"4767_CR26","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1002\/jmri.27141","volume":"52","author":"SB Hong","year":"2020","unstructured":"Hong SB, Lee NK, Kim S, Son IW, Ha HK, Ku JY, Kim KH, Park WY. Vesical Imaging-Reporting and Data System for Multiparametric MRI to Predict the Presence of Muscle Invasion for Bladder Cancer. J Magn Reson Imaging. 2020 Oct;52(4):1249-1256.","journal-title":"J Magn Reson Imaging."},{"key":"4767_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.903297","volume":"13","author":"HK Chae","year":"2022","unstructured":"Chae HK, Nam W, Kim HG, Lim S, Noh BJ, Kim SW, Kang GH, Park JY, Eom DW, Kim SJ. Identification of New Prognostic Markers and Therapeutic Targets for Non-Muscle Invasive Bladder Cancer: HER2 as a Potential Target Antigen. Front Immunol. 2022 May;13:903297.","journal-title":"Front Immunol."},{"key":"4767_CR28","doi-asserted-by":"crossref","unstructured":"Ge L, Chen Y, Yan C, Zhao P, Zhang P, A R, Liu J. Study Progress of Radiomics With Machine Learning for Precision Medicine in Bladder Cancer Management. Front Oncol. 2019 Nov;9:1296.","DOI":"10.3389\/fonc.2019.01296"},{"key":"4767_CR29","unstructured":"Tramanzoli P, Castellani D, De Stefano V, Brocca C, Nedbal C, Chiacchio G, Galosi AB, Da Silva RD, Teoh JY, Tiong HY, Naik N, Somani BK, Gauhar V. Radiomics vs radiologist in bladder and renal cancer. Results from a systematic review. Cent European J Urol. 2023;76(1):12\u201319."},{"issue":"22","key":"4767_CR30","doi-asserted-by":"publisher","first-page":"5468","DOI":"10.3390\/cancers15225468","volume":"15","author":"O Akin","year":"2023","unstructured":"Akin O, Lema-Dopico A, Paudyal R, Konar AS, Chenevert TL, Malyarenko D, Hadjiiski L, Al-Ahmadie H, Goh AC, Bochner B, Rosenberg J, Schwartz LH, Shukla-Dave A. Multiparametric MRI in Era of Artificial Intelligence for Bladder Cancer Therapies. Cancers (Basel). 2023 Nov;15(22):5468.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"4767_CR31","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.acra.2022.04.014","volume":"30","author":"Y Liu","year":"2023","unstructured":"Liu Y, Xu X, Wang H, Liu Y, Wang Y, Dong Q, Li Z, Guo Y, Lu H. The Additional Value of Tri-parametric MRI in Identifying Muscle-invasive Status in Bladder Cancer. Acad Radiol. 2023 Jan;30(1):64-76.","journal-title":"Acad Radiol."},{"issue":"1145","key":"4767_CR32","doi-asserted-by":"publisher","first-page":"20221086","DOI":"10.1259\/bjr.20221086","volume":"96","author":"X Fan","year":"2023","unstructured":"Fan X, Yu H, Ni X, Chen G, Li T, Chen J, He M, Liu H, Wang H, Yin X. Systematic radiomics analysis based on multiparameter MRI to preoperatively predict the expression of Ki67 and histological grade in patients with bladder cancer. Br J Radiol. 2023 Apr;96(1145):20221086.","journal-title":"Br J Radiol."},{"issue":"3","key":"4767_CR33","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1007\/s00330-023-10137-w","volume":"34","author":"J Huang","year":"2024","unstructured":"Huang J, Chen G, Liu H, Jiang W, Mai S, Zhang L, Zeng H, Wu S, Chen CY, Wu Z. MRI-based automated machine learning model for preoperative identification of variant histology in muscle-invasive bladder carcinoma. Eur Radiol. 2024 Mar;34(3):1804-1815.","journal-title":"Eur Radiol."},{"issue":"2","key":"4767_CR34","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.222646","volume":"308","author":"T Ramtohul","year":"2023","unstructured":"Ramtohul T, Djerroudi L, Lissavalid E, Nhy C, Redon L, Ikni L, Djelouah M, Journo G, Menet E, Cabel L, Malhaire C, Tardivon A. Multiparametric MRI and Radiomics for the Prediction of HER2-Zero, -Low, and -Positive Breast Cancers. Radiology. 2023 Aug;308(2):e222646.","journal-title":"Radiology."},{"issue":"12","key":"4767_CR35","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.21037\/tcr-22-1690","volume":"11","author":"T Ma","year":"2022","unstructured":"Ma T, Cui J, Wang L, Li H, Ye Z, Gao X. A CT-based radiomics signature for prediction of HER2 overexpression and treatment efficacy of trastuzumab in advanced gastric cancer. Transl Cancer Res. 2022 Dec;11(12):4326-4337.","journal-title":"Transl Cancer Res."},{"issue":"6","key":"4767_CR36","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1002\/jmri.29342","volume":"60","author":"R Yu","year":"2024","unstructured":"Yu R, Cai L, Gong Y, Sun X, Li K, Cao Q, Yang X, Lu Q. MRI-Based Machine Learning Radiomics for Preoperative Assessment of Human Epidermal Growth Factor Receptor 2 Status in Urothelial Bladder Carcinoma. J Magn Reson Imaging. 2024 Dec;60(6):2694-2704.","journal-title":"J Magn Reson Imaging."},{"issue":"7","key":"4767_CR37","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1007\/s00261-024-04378-6","volume":"49","author":"L Kong","year":"2024","unstructured":"Kong L, Ling J, Cao W, Wen Z, Lin Y, Cai Q, Chen Y, Guo Y, Chen J, Wang H. Multiparametric MR characterization for human epithelial growth factor receptor 2 expression in bladder cancer: an exploratory study. Abdom Radiol (NY). 2024 Jul;49(7):2349-2357.","journal-title":"Abdom Radiol (NY)."}],"container-title":["Abdominal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-024-04767-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00261-024-04767-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-024-04767-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T03:01:53Z","timestamp":1757127713000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00261-024-04767-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":37,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["4767"],"URL":"https:\/\/doi.org\/10.1007\/s00261-024-04767-x","relation":{},"ISSN":["2366-0058"],"issn-type":[{"value":"2366-0058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"assertion":[{"value":"20 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The following article note was missed in the published version: Cheng Luo and Shurong Li contributed equally to this work.\nHowever, now it is corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}